New drugs in psychiatry: focus on new pharmacological targets

Filippo Caraci, Gian Marco Leggio, Salvatore Salomone, Filippo Drago

Research output: Contribution to journalReview article

Abstract

The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years. To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications. In this report, we detail drug candidates being examined as treatments for psychiatric disorders. Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer's disease. All of the compounds considered were recently approved for human use or are in advanced clinical trials. Drugs included here are new antipsychotic medications endowed with a preferential affinity at dopamine D3 receptor (cariprazine) or at glutamatergic or cannabinoid receptors, as well as vortioxetine, a drug approved for managing the cognitive deficits associated with major depression. New mechanistic approaches for the treatment of depression include intravenous ketamine or esketamine or intranasal esketamine. As for Alzheimer's disease, the possible value of passive immunotherapy with agents such as aducanumab is considered to be a potential disease-modifying approach that could slow or halt the progressive decline associated with this devastating disorder.

Original languageEnglish
Pages (from-to)397
JournalF1000Research
Volume6
DOIs
Publication statusPublished - 2017

Fingerprint

Psychiatry
Pharmacology
Depression
Alzheimer Disease
Pharmaceutical Preparations
Dopamine D3 Receptors
Cannabinoid Receptors
Passive Immunization
Psychotropic Drugs
Ketamine
Antipsychotic Agents
Schizophrenia
Therapeutics
Clinical Trials
aducanumab
cariprazine
vortioxetine

Keywords

  • Journal Article
  • Review

Cite this

New drugs in psychiatry : focus on new pharmacological targets. / Caraci, Filippo; Leggio, Gian Marco; Salomone, Salvatore; Drago, Filippo.

In: F1000Research, Vol. 6, 2017, p. 397.

Research output: Contribution to journalReview article

Caraci, Filippo ; Leggio, Gian Marco ; Salomone, Salvatore ; Drago, Filippo. / New drugs in psychiatry : focus on new pharmacological targets. In: F1000Research. 2017 ; Vol. 6. pp. 397.
@article{1abe84a971cb417686b926ee97e6a408,
title = "New drugs in psychiatry: focus on new pharmacological targets",
abstract = "The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years. To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications. In this report, we detail drug candidates being examined as treatments for psychiatric disorders. Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer's disease. All of the compounds considered were recently approved for human use or are in advanced clinical trials. Drugs included here are new antipsychotic medications endowed with a preferential affinity at dopamine D3 receptor (cariprazine) or at glutamatergic or cannabinoid receptors, as well as vortioxetine, a drug approved for managing the cognitive deficits associated with major depression. New mechanistic approaches for the treatment of depression include intravenous ketamine or esketamine or intranasal esketamine. As for Alzheimer's disease, the possible value of passive immunotherapy with agents such as aducanumab is considered to be a potential disease-modifying approach that could slow or halt the progressive decline associated with this devastating disorder.",
keywords = "Journal Article, Review",
author = "Filippo Caraci and Leggio, {Gian Marco} and Salvatore Salomone and Filippo Drago",
year = "2017",
doi = "10.12688/f1000research.10233.1",
language = "English",
volume = "6",
pages = "397",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - New drugs in psychiatry

T2 - focus on new pharmacological targets

AU - Caraci, Filippo

AU - Leggio, Gian Marco

AU - Salomone, Salvatore

AU - Drago, Filippo

PY - 2017

Y1 - 2017

N2 - The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years. To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications. In this report, we detail drug candidates being examined as treatments for psychiatric disorders. Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer's disease. All of the compounds considered were recently approved for human use or are in advanced clinical trials. Drugs included here are new antipsychotic medications endowed with a preferential affinity at dopamine D3 receptor (cariprazine) or at glutamatergic or cannabinoid receptors, as well as vortioxetine, a drug approved for managing the cognitive deficits associated with major depression. New mechanistic approaches for the treatment of depression include intravenous ketamine or esketamine or intranasal esketamine. As for Alzheimer's disease, the possible value of passive immunotherapy with agents such as aducanumab is considered to be a potential disease-modifying approach that could slow or halt the progressive decline associated with this devastating disorder.

AB - The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years. To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications. In this report, we detail drug candidates being examined as treatments for psychiatric disorders. Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer's disease. All of the compounds considered were recently approved for human use or are in advanced clinical trials. Drugs included here are new antipsychotic medications endowed with a preferential affinity at dopamine D3 receptor (cariprazine) or at glutamatergic or cannabinoid receptors, as well as vortioxetine, a drug approved for managing the cognitive deficits associated with major depression. New mechanistic approaches for the treatment of depression include intravenous ketamine or esketamine or intranasal esketamine. As for Alzheimer's disease, the possible value of passive immunotherapy with agents such as aducanumab is considered to be a potential disease-modifying approach that could slow or halt the progressive decline associated with this devastating disorder.

KW - Journal Article

KW - Review

U2 - 10.12688/f1000research.10233.1

DO - 10.12688/f1000research.10233.1

M3 - Review article

C2 - 28408985

VL - 6

SP - 397

JO - F1000Research

JF - F1000Research

SN - 2046-1402

ER -